Five Penny Stocks with Heavy Volume to Watch for Monday

By / / Hot Stocks to Watch


RXI Pharmaceuticals (OTC:RXII) traded as high as $.20 during Friday’s trading session and last traded at $.15 for a gain of 15.38% from Thursday’s close… RXII shares have traded as high as $.20 over the past 52 weeks, which is 0% off that high at last traded stock price. Get my next ALERT 100% FREE

RXi Pharmaceuticals Corporation is a biotechnology company focused on discovering, developing and commercializing innovative therapies based on its proprietary, next-generation RNAi platform.

Oryon Technologies Inc (PINK:ORYN) traded as high as $1.24 during Friday’s trading session and last traded at $1.20 for a gain of 7.14% from Thursday’s close… ORYN shares have traded as high as $1.21 over the past 52 weeks, which is .83% off that high at last traded stock price.


Oryon Technologies, formerly Oryon Holdings, is an exploration-stage company engaged in the exploration of mineral properties for gold. The Company purchased a 100% interest in the Tabuk Gold property, which consists of a prospect that contains one seven-unit claim block containing 955.2 hectares.

RarusTechnologies (PINK:RARS) traded as high as $.35 during Friday’s trading session and last traded at $.183 for a loss of 48.61% from Thursday’s close… RARS shares have traded as high as $.59 over the past 52 weeks, which is 68.98% off that high at last traded stock price.

Rarus Minerals, Inc., an exploration stage corporation, engages in the acquisition, exploration, and development of rare earth mineral properties.

PolyMedix, Inc. (OTC:PYMX) traded as high as $.405 during Friday’s trading session and last traded at $.355 for a loss of 39.32% from Thursday’s close… PYMX shares have traded as high as $1.50 over the past 52 weeks, which is 76.33% off that high at last traded stock price. Get my next ALERT 100% FREE

PolyMedix is a clinical stage biotechnology company developing first-in-class, small-molecule drugs for the treatment of serious acute care conditions. PolyMedix has two lead compounds and a pipeline of innovative infectious disease and cardiovascular product candidates, all of which were internally developed using a proprietary drug discovery technology platform.

Sefe Incorporated (OTC:SEFE) traded as high as $.905 during Friday’s trading session and last traded at $.73 for a loss of 18.44% from Thursday’s close… SEFE shares have traded as high as $2.96 over the past 52 weeks, which is 75.34% off that high at last traded stock price.

SEFE focuses on pushing the boundaries of what’s possible, embracing innovation and employing the cutting-edge to solve problems, and offering sustainable solutions to a world hungry for invention, direction and leadership.

 

More Posts by this author

Post Written By: Oliver Crowne

Oliver Crowne is the main editor for http://www.StockPreacher.com


Disclaimer: This article is for informational purposes only and does not constitute financial advice. We are not financial professionals. The authors and/or site operators may hold positions in the companies or assets mentioned. Always do your own research before making financial decisions.